baber/WOPTO huggingface dataset:
Patent NZ-320692-A (NZ)
Title: Screening arrangement for screening pulp suspensions
Inventor: FREDRIKSSON BORJE
IPC: D21D5/02
Filed: 1996-09-26
Abstract: PCT No. PCT/SE96/01204 Sec. 371 Date Apr. 7, 1998 Sec. 102(e) Date Apr. 7, 1998 PCT Filed Sep. 26, 1996 PCT Pub. No. WO97/13919 PCT Pub. Date Apr. 17, 1997Apparatus for screening pulp suspensions containing heavy impurities is disclosed including a casing with an inlet for the pulp suspension at the lower end of the casing, a stationary screen mounted within the casing, a rotor mounted for rotation within the stationary screen thus forming a screening zone between the rotor and the stationary screen, with the inlet disposed within the rotor, the rotor including at least one opening adjacent to its upper end for transferring the pulp into the screening zone and a chamber for the heavy impurities disposed adjacent to either the upper or lower end of the casing, the rotor including strips or grooves for moving heavy impurities from the inner surface of the rotor to the chamber.
Patent NZ-327052-A (NZ)
Title: Novel substituted imidazole compounds
Inventor: ADAMS JERRY L
IPC: A61P33/06
Filed: 1997-01-10
Abstract: he present invention relates to 1, 4, 5-substituted imidazole compounds of the formula 1 where: R1 is 4-pyrimidinyl ring substituted with a C1-4 alkoxy and is optionally substituted independently by C1-4 alkyl, halogen, hydroxyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylsulfinyl, CH2OR12, amino, mono and di-C1-6 alkyl substituted amino, N(R10)C(O)Rc or an N-heterocyclyl which ring has 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15: R4 is phenyl, naphthy-1-yl or naphth-2-yl or a heteroaryl optionally substituted as defined in the claims R2 is an optionally substituted heterocyclyl or an optionally substituted heterocyclylC1-10 alkyl moiety. Also claimed is the use of the compound for use in therapy as cytokine inhibitor, and the process for preparing the compound.
Patent NZ-331024-A (NZ)
Title: Mixture of recombinant vaccinia vectors as polyenv vaccines for HIV from recombinant vaccinia viruses each expressing a different variant of HIV envelope protein
Inventor: HURWITZ JULIA
IPC: C12N/
Filed: 1997-01-23
Abstract: Polyenv vaccines are provided that comprise mixtures of at least 4 to about 10.000 different recombinant viruses that each express a different HIV env variant or a portion thereof containing both constant and variable regions, as well as methods of making and using such polyenv vaccines and viruses, including the use of the polyenv vaccine, in live, attenuated or inactivated form, for prophylaxis or treatment of HIV infection. The viral vaccines of the invention are optimally combined with a recombinant HIV env booster, or a recombinant HIV env gene DNA priming or boosting vaccine.
Patent NZ-331343-A (NZ)
Title: Condoms foldable flat
Inventor: RUDGE JANETTE MARY
IPC: A61F6/06
Filed: 1997-02-14
Abstract: A condom has a ring (6) adjacent the open end (1) for expanding the condom to a maximum diameter to maintain the open end outside the vagina, and a tubular portion (3) extending between the ring and the closed end is of a size to form a loose fit around the penis and is formed with a series of circumferential grooves (5), e.g. 3 to 5 grooves around 0.8 cm wide and 1.0 cm deep, so that the condom naturally folds in a bellows like manner for the condom to collapse to a substantially flat condition prior to use.
Patent NZ-331733-A (NZ)
Title: Fragments of cr1 and their use
Inventor: MOSSAKOWSKA DANUTA EWA IRENA
IPC: A61K38/00
Filed: 1997-02-26
Abstract: A polypeptide comprising a portion of the sequence of the general formula (I): CNPGSGGRKVFELVGEPSIYCTSNDDQVGIWSG, of 6-23 amino acids in length and comprising sequence a) and/or b): a) GGRKVF, b) FELVGEPSIY multimeric and chimeric derivatives, pharmaceutiocal compositions containing them and their use in therapy.
Patent NZ-335280-A (NZ)
Title: D-penicillamine derivatives for treating beta-amyloid type diseases such as Alzheimer's disease
Inventor: NISSEN JEFFERY S
IPC: C07C327/22
Filed: 1997-11-21
Abstract: A use of the compound of Formula (I) for treating diseases associated with b-amyloid peptide release or for the prevention of the onset of AD. Wherein; R1 is selected from the group consisting of:  (a) alkyl, alkenyl, alkaryl, alkcycloalkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocyclic group is optionally substituted with 1 to 3 substituents selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, halo, nitro, thioalkoxy and thioaryloxy; (b) a substituted phenyl group of Formula (II); wherein R is C1-8alkylene, m is an integer equal to 0 or 1, Ra and Ra' are independently selected from the group consisting of hydrogen, hydroxy, fluoro and methyl; Rb and Rb' are independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, cyano, cycloalkyl, halo, heteroaryl, heteroaryloxy, heterocyclic, nitro, trihalomethyl, thioalkoxy, thioaryloxy, thioheteroaryloxy and -C(O)R4 where R4 is selected from the group consisting of alkyl, aryl, and alkoxy and aryloxy; and Rc is selected from the group consisting of hydrogen, alkyl, aryl, cyano, halo, nitro and where Rb and Rc are fused to form a methylenedioxy ring with the phenyl ring when Rb and/or Rb' and/or Rc is fluoro, chloro, bromo and/or nitro, then Ra and/or Ra' can also be chloro; and (c) 1- or 2-naphthyl substituted at the 5, 6, 7 and/or 8 positions with 1-4 substituents selected from the group consisting of alkyl, alkoxy, halo, cyano, nitro, trihalomethyl and thioalkoxy; R2 is selected from the group consisting of hydrogen, C1-4alkyl, C1-4alkylalkoxy, C1-4alkylthioalkoxy and R3 and R3' are independently selected from the group consisting of: (a) hydrogen with the proviso that R3 and R3' cannot be hydrogen; (b) alkyl with the proviso that when R3 is hydrogen, then the R3' alkyl group has a linear carbon chain length of at least 5 carbon atoms from the nitrogen atom which chain can be optionally substituted with one or more alkyl groups with the proviso that only one of R3 and R3' being at least C1-5alkyl; (c) -(RR7)n(W)p wherein R7 is an alkylene group, W is selected from the group consisting of Formula (III); (d) -CH(f)CH2C(O)O-Q where Q is selected from the group consisting of alkyl, aryl, heteroaryl and heterocyclic.
Patent NZ-509918-A (NZ)
Title: Isolated and purified human soluble guanylylcyclase alpha-1/beta-1 (hsGC alpha-1/beta-1) and its use in cardiac diseases
Inventor: SCHMIDT HARALD
IPC: C12N15/62
Filed: 1999-08-16
Abstract: Isolated human soluble guanylyl cyclase a1 (hsGCa1; SEQ ID NO: 2)/b1 (hsGCb1:;SEQ ID No:4) purified to apparent homogeneity. The nucleotide encoding the cyclase can be used for the prevention and therapy of artherosclerosis and its complications, of restenosis, ischemia (infarction) peripheral arterial occlusive diseases, and arterial hypertension as well as for the prevention of artherosclerosis in patients with risk factors, transient ischemic attacks, cerebral ischemia, stroke (Apoplex), coronary heart disease, status post coronary bypass grafting, carotid stenosis, heart insufficiency and liver dysfunction, and as a supplement to therapy with sGC activators, sGC-sensitizing substances, NO donors, or phosphodiesterase inhibitors.
Patent NZ-510706-A (NZ)
Title: Deep conversion combining the demetallization and the conversion of crudes, residues or heavy oils into light liquids with pure or impure oxygenated compounds
Inventor: JORGENSEN PIERRE
IPC: C10G33/08
Filed: 1999-10-07
Abstract: A process for the conversion of hydrocarbons containing residues  or  heavy  distillates which  may  be  laden  with impurities  into light products that may be  distilled,  the process comprising; preheating a hydrocarbon load to first temperature; treating  the  load  with a jet having  a  first  amount  of energy,  activating  the  load by transferring  at  least  a portion  of the first amount of energy to the load at  which at  least a portion of the molecules of the load split  into lighter molecules; stabilizing the load at a second temperature in  a  reactor, wherein the reactor is operated at a first pressure; and expending the load at a second pressure and passing the load through   a   series  of  extractors  being  configured   to demetalise  the  load, at least one of the extractors  being configured to produce water/hydrocarbon emulsions.
Patent NZ-511023-A (NZ)
Title: Adhesive composition comprising polyisocyanate (diphenylmethane diisocyanate) and a wax emulsion (paraffin wax) with emulsifier (ethylene oxide polyaddition)
Inventor: YOSHIDA MITSUHIRO
IPC: B27N3/00
Filed: 2001-04-09
Abstract: An adhesive composition for producing forms wherein lignocellulose-type material is used, hot pressed forms using the adhesive composition thereof having superior physical properties; such as resistance to hot water, and a process for producing hot pressed forms. The composition comprises (a) an organopolyisocyanate which is a polyisocyanate composed of 20% to 70% by weight of a diphenylmethane diisocyanate having two benzene rings in one molecule and from 80% to 30% by weight of a diphenylmethane diisocyanate polynuclear condensate having at least three benzene rings in one molecule, and has a viscosity of 500 mPa or less when in a solid state content of 100% by weight at 25oC; and (b) a wax emulsion prepared by emulsifying a wax (B1) which is paraffin wax containing at least 80% by weight of a paraffin having 20 to 40 carbon atoms, and has a melting point of from 40oC to 100oC, with an emulsifier (B2) which is an ethylene oxide polyaddition product of an aliphatic monoalcohol whose aliphatic chain has 14 to 20 carbon atoms, and a process for producing the hot-pressed forms using this adhesive composition.
Patent NZ-514177-A (NZ)
Title: A process for the preparation of thiazolidine derivatives
Inventor: OKUMOTO ITSUO
IPC: C07D277/34
Filed: 2000-03-16
Abstract: A method of preparing a thiazolidine of formula (I) comprises reacting a compound of formula (II) with a compound of formula (V) in the presence of an alkali metal in liquid ammonia wherein D is naphthyl or an optionally substituted phenyl; A is alkylene and X is halogen.
Patent NZ-514897-A (NZ)
Title: Method of treatment of containerized fruit product using a gas mixture
Inventor: MITCHELL JERRY L
IPC: B65B25/00
Filed: 2000-05-25
Abstract: A method of treating a perishable fruit product is disclosed, which includes the following steps: sealing the fruit product within a container; tempering the product to between 45-80°F; introducing a tempered and humidified gas mixture into the container to slow the ripening process, wherein the gas mixture comprises a combination of inert gas and is maintained around the product for a predetermined residence time to delay the oxidation and dehydration process of the product.
Patent NZ-518098-A (NZ)
Title: Tobacco pouch
Inventor: VAN GERWEN MARIA PETRONELLA HE
IPC: B65D33/24
Filed: 2000-09-29
Abstract: The  invention relates to a tobacco pouch (1) provided with  a front wall (2) and a back wall (4) manufactured from plastic  film and with a flap (6) attached to the back  wall (4).  The  tobacco pouch is further provided with connecting means  for  closing  off  the tobacco  pouch  by  releasably connecting the flap to the front wall. The connecting  means comprise  a first part (12) which is connected to  the  flap (6)  and a second part (14) which is connected to the  front wall  (2). One of the two parts is provided with hooks  (18) which  can  be  releasably fastened  to  co-operating  means provided  on  the  other of the two  parts.  The  first  and second  parts (12, 14) consist of a strip-shaped  area,  the lengthwise  direction (16, 22) of one of which is  at  least substantially  directed parallel to the side edge  (8)  when the flap (6) is connected to the front wall (2).
Patent NZ-519129-A (NZ)
Title: Fluorescent cobalamins and uses thereof
Inventor: GRISSOM CHARLES B
IPC: G01N33/574
Filed: 2000-10-26
Abstract: Disclosed is a cobalamin of formula I wherein: R1 is CN, OH, OH2, CH3, 5'-deoxyadenosyl or (CH2)pNHC(=S)Y; R2, R3, R6 and R7 are CONH2 R8 is CH2OH or O(C=O)X-mY; R9 is OH or O(C=O)X-mY; X is a linker having the formula NH(CH2)NHO(C=O); and Y is a fluorophore, phosphorophore, or a chemiluminescent chromophore. The said cobalamin fluoresces, phosphoresces or luminesces when illuminated with ultraviolet, visible or infrared light without cleavage of Y from the cobalamin. The compound is useful for the in vitro or ex vivo detection of cancerous tissue and metastatic cancer and in determining whether an individual will respond positively to cobalamin-therapeutic bioconjugates.
Patent NZ-520138-A (NZ)
Title: Integrated convection and conduction heat sink for multiple mounting positions
Inventor: TEHAN MATTHEW A
IPC: H05K7/20
Filed: 2000-12-11
Abstract: An integrated thermal management system for electronic devices includes a printed wiring board (13) for supporting electronic devices, at least one die-up and one die-down electronic device (51, 53), a frame (15) and a heat sink. The board (13) includes at least one thermally conductive layer, to which the die-down device (51, 53) is thermally connected. The frame member (15), which includes at least a first heat sink mounting location, is connected to one of the first (63) and second surfaces (65) of the board (13), adjacent to the edge. The heat sink itself, which is cantilevered over the die-up electronic device from at least one heat sink mounting location (63, 65), includes a portion, which is adapted to engage the die-up electrical device, a portion (63, 65) connected to the frame member (15) to provide a conductive path from the die-up device to the frame member (15), and a convective cooling portion (129). The thermal management structure also includes a cold wall, which engages the frame (15) to provide a thermally conductive connection between the frame member (15) and the cold wall. The heat sink(s) (17) covers only the die-up electronic device(s) and those portions of the board surface(s) between the die-up electronic device(s) and the frame necessary to thermally connect the die-up electronic device(s) to the frame (15), to thereby provide access to the board surfaces for inspection or testing without removal of the heat sink(s).
Patent NZ-520474-A (NZ)
Title: Combined herbal preparation comprising Leucojum aestivum, coenzyme Q10 and B group vitamins to treat conditions exacerbated by oestrogen loss
Inventor: GROSE TRICIA
IPC: A61P25/00
Filed: 2000-01-28
Abstract: Oestrogen-deficiency related cognitive dysfunction may be treated by administering an herbal composition to a female. The composition comprising about 0.33wt% whole plant extract of Leucojum aestivum; about 0.03 wt% B group vitamins; 39.6 wt% acetyl L-carnitine; 3.96 wt% Co-Q10 ; 1.98 wt% zinc, 10.56 wt% gingko biloba extract; 19.8% Bacopa monniera and about 19.8% convolvulus pluricaulis.
Patent NZ-520716-A (NZ)
Title: Device for the articulated connection of two bodies
Inventor: SCHLAPFER FRIDOLIN
IPC: A61B17/64
Filed: 2000-04-19
Abstract: The invention relates to a device for the articulated connection of two bodies. Said device comprises A) a first body (1) which contains a hollow chamber (5) that is positioned coaxially in relation to a central axis (6); B) a clamping element (8) comprising a longitudinal axis (11) and a coaxial bore (15) with at least one opening (50) that adjoins said bore, whereby the clamping element (8) is configured in such a way that it can be elastically deformed in a complementary manner in relation to the hollow chamber (5) and perpendicular to the longitudinal axis (11); C) at least one tensioning element (12) which can be introduced into the opening (50) coaxially in relation to the longitudinal axis (11) and which can extend in an axial direction; D) a second body (2), which can be detachably connected to the first body (1) using the tensioning element(s) (12) and the clamping element (8); E) a drive element (19) which can be used to displace the tensioning element(s) (12) axially in relation to the opening (50), whereby F) the drive element (19) is connected axially to both the clamping element (8) and the tensioning element(s) (12) in a positive fit and in such a way that it can be rotated about the longitudinal axis (11).
Patent NZ-524961-A (NZ)
Title: Mixing high temperature gases in mineral kilns
Inventor: HANSEN ERIC R
IPC: C04B7/44
Filed: 2001-09-12
Abstract: A method is described for reducing NOx emissions and improving energy efficiency during mineral processing in a rotary kiln. The method comprises injection of air with high velocity/high kinetic energy into the kiln to reduce or eliminate stratification of kiln gases. The method can be applied to mix gases in a rotary kiln vessel or in a preheater/pecalciner vessel.
Patent NZ-528979-A (NZ)
Title: Movement suggestion and motivation methods and related means
Inventor: MACINNES CARL JOHN
IPC: G09F19/22
Filed: 2002-04-19
Abstract: The present invention relates to a display for motivating or inducing behaviour or arousal in a subject. It includes a plurality of image frames displayed in a stereograph which may be used to motivating, inducing or discourage a specified behaviour or form of arousal. One application is use in a public area such as a retail environment with a small number of the image frames include symbols to either encourage or discourage the consumer from moving towards or away from desired product and/or encourage purchase of the product. Product brands and or slogans may also be included in one or more frames.
Patent NZ-531230-A (NZ)
Title: Golf driving mat
Inventor: SEAR PHILIP GEORGE
IPC: A63B69/36
Filed: 2002-08-20
Abstract: A golf driving mat, including: a flexible member (21) over which a golf ball is in use located to be hit by a head of a golf club; and a cavity (23) containing a viscous material (25) disposed beneath the flexible member, wherein the viscous material is such as to slow the head of the golf club when the head of the golf club is hit into the flexible member, such a shot representing a "fat" shot.
Patent NZ-532491-A (NZ)
Title: Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Inventor: ALOBA OLUWOLE T
IPC: A61P25/28
Filed: 2002-12-20
Abstract: Disclosed is a pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17B-estradiol-3-acetate and a pharmaceutically acceptable carrier, wherein the percent moisture of the dosage unit is less than or equal to 8%. Also disclosed is the use of 17B-estradiol-3-lower alkanoate for the preparation of a dosage unit wherein the dosage unit is prepared for oral administration. The dosage units are used in methods of providing contraception by administration to human females of child bearing age.
Patent NZ-532669-A (NZ)
Title: Method and apparatus for detecting holes in plastic containers
Inventor: BOGSTAD DAVID A
IPC: G01N29/14
Filed: 2002-10-31
Abstract: A method and an apparatus for monitoring the production of blow moulded plastic containers 20 are disclosed. The apparatus includes a sound detector 24 responsive to a defect sound of pressure fluid escaping from a container being formed in a mould cavity 14 and a columnator 26 to filter the defect sound from ambient noise. An output signal generated by the sound detector is processed to generate a control signal used to reject a defective container. The open end of the columnator is positioned between 20 DEG and 150 DEG from the preform loading station in a rotary platform 12 blow moulding machine.
Patent NZ-532772-A (NZ)
Title: Method and system for updating a remote database
Inventor: BALOGH ARISTOTLE NICHOLAS
IPC: G06F17/00
Filed: 2002-11-01
Abstract: A remote database 210 is updated over a network. A plurality of periodic updates, called sendfiles 300-F, based on incremental changes to a local database 200 are generated. Each sendfile includes at least one database transaction. An initialization update, called an initializing sendfile 310, which includes a version of the local database at a start time is generated. Additionally, an identifier associated with the last periodic update generated before the start time and an identifier associated with the last transaction committed prior to the start time are generated.
Patent NZ-536455-A (NZ)
Title: Mycophenolate mofetil in diabetic nephropathy
Inventor: MOORTHY SACHIDANANDA
IPC: A61P3/10
Filed: 2004-05-05
Abstract: Use of a combination of an immunosuppressive agent such as mycophenolate mofetil and an ACE inhibitor such as lisinopril for the manufacture of a medicament for treating or lessening the severity of diabetic nephropathy or lupus nephropathy is disclosed.
Patent NZ-538813-A (NZ)
Title: Intra-ruminal bolus for the controlled release of a beneficial agent
Inventor: MUNDAY REX
Filed: 2005-03-14
Abstract: An intra-ruminal bolus that releases a therapeutically effective amount of at least one beneficial agent to a ruminant animal over a time period of less than approximately 21 days that includes: (a) at least one beneficial agent; (b) at least one densifier material; (c) at least one binding agent; (d) at least one releasing agent; and, characterised in that the ratio of binding agent to releasing agent ranges from approximately 1 part binding agent to between approximately 0.01 and approximately 2 parts releasing agent to achieve a sustained release rate over a time period of less than approximately 21 days.
Patent NZ-542626-A (NZ)
Title: Nanoporous ultrafine alpha-alumina powders and freeze drying process of preparing the same
Inventor: WANG YUHU
IPC: C01F7/023
Filed: 2004-03-31
Abstract: A nanoporous alpha-alumina powder is disclosed, which comprises interconnected alpha-alumina primary particles having an average particle size of less than about 100 nm and an interpenetrated array of pores or voids, which are prepared by a process comprising the steps of: providing an inorganic sol comprising at least one alumina precursor and a plurality of alpha-alumina seed particles; adding at least one water soluble organic polymer to the inorganic sol to form an organic-inorganic sol; freeze drying the organic-inorganic sol to form a solid gel; and firing the solid gel at a temperature capable of combusting the organic polymer and inducing alpha-alumina formation of a nanoporous alpha-alumina powder comprising interconnected alpha-alumina primary particles. The disclosure also provides nanosized alpha-alumina powders comprising alpha-alumina particles having an average particle size of less than about 100 nm and slurries, particularly aqueous slurries, which comprise nanosized alpha-alumina powders of the invention. The disclosure further provides methods of manufacturing nanoporous alpha-alumina powders and nanosized alpha-alumina powders of the invention and methods of polishing using slurries of the invention.
Patent NZ-544162-A (NZ)
Title: Abuse resistant amphetamine compounds
Inventor: MICKLE TRAVIS
IPC: A61K31/165
Filed: 2004-06-01
Abstract: Disclosed is a compound selected from the group consisting of L-lysine-d-amphetamine and a pharmaceutically acceptable salt thereof. Also disclosed is a pharmaceutical composition comprising an unprotected prodrug and one or more pharmaceutically acceptable additives, wherein, the prodrug consists of the above compound; wherein the composition is in a form suitable for oral administration; wherein the composition provides release of amphetamine as an active ingredient from the prodrug following oral administration; and wherein the prodrug has limited bioavailability of amphetamine when administered through alternative routes of administration.